ENTA — Enanta Pharmaceuticals Balance Sheet
0.000.00%
- $306.94m
- $104.17m
- $67.64m
- 37
- 13
- 95
- 46
Annual balance sheet for Enanta Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 387 | 244 | 249 | 370 | 248 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 23.5 | 60.8 | 49 | 39.6 | 38.6 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 437 | 319 | 312 | 423 | 300 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15.6 | 10.7 | 29.7 | 34.7 | 73.3 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 486 | 439 | 375 | 462 | 377 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 24.2 | 36.2 | 29.8 | 62.8 | 57.5 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 30.6 | 39.4 | 54.1 | 246 | 248 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 456 | 399 | 321 | 217 | 129 |
| Total Liabilities & Shareholders' Equity | 486 | 439 | 375 | 462 | 377 |
| Total Common Shares Outstanding |